Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Gunhild Keller"'
Autor:
Daniel Benten, Gunhild Keller, Alexander Quaas, Jorg Schrader, Artur Gontarewicz, Stefan Balabanov, Melanie Braig, Henning Wege, Jurgen Moll, Ansgar W. Lohse, Tim H. Brummendorf
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 11, Iss 9, Pp 934-944 (2009)
Patients with advanced stages of hepatocellular carcinoma (HCC) face a poor prognosis. Although encouraging clinical results have been obtained with multikinase inhibitor sorafenib, the development of improved therapeutic strategies for HCC remains a
Externí odkaz:
https://doaj.org/article/f44d5427273e43cfa4258d1f4c805c2b
Autor:
Stefan Balabanov, Thomas Wilhelm, Simone Venz, Gunhild Keller, Christian Scharf, Heike Pospisil, Melanie Braig, Christine Barett, Carsten Bokemeyer, Reinhard Walther, Tim H Brümmendorf, Andreas Schuppert
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53668 (2013)
In drug discovery, the characterisation of the precise modes of action (MoA) and of unwanted off-target effects of novel molecularly targeted compounds is of highest relevance. Recent approaches for identification of MoA have employed various techniq
Externí odkaz:
https://doaj.org/article/f5ef203a54d44cec9bc3e7b68936836e
Autor:
Stefan Balabanov, Artur Gontarewicz, Gunhild Keller, Laura Raddrizzani, Melanie Braig, Roberta Bosotti, Jürgen Moll, Edgar Jost, Christine Barett, Imke Rohe, Carsten Bokemeyer, Tessa L Holyoake, Tim H Brümmendorf
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e19164 (2011)
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells. Danusertib (formerly PHA-739358) is a potent pan-aurora and ABL kinase i
Externí odkaz:
https://doaj.org/article/cfe0611edd20497280a5b2f6003a51ea
Autor:
Sergey A. Dyshlovoy, N. D. Pokhilo, Carsten Bokemeyer, Dmitry N. Pelageev, Vladimir A. Denisenko, Sergey N. Fedorov, Victor Ph. Anufriev, Gunhild Keller-von Amsberg, Friedemann Honecker, Ksenia L. Borisova
Publikováno v:
European Journal of Medicinal Chemistry. 77:139-144
We have found that 2-methoxy-1,4-naphthoquinones easily react with primary alcohols to produce the corresponding 2-alkoxyderivatives. Using this reaction, we synthesized methyl-6- O -(naphthalene-1,4-dione-2-yl)- α -D-glucopyranosides, a new type of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe5b36ec7080b53383efaa25a18e142
https://doi.org/10.1016/j.ejmech.2014.03.006
https://doi.org/10.1016/j.ejmech.2014.03.006
Autor:
Daniel Benten, Miklós Jászberényi, Luca Szalontay, Irving Vidaurre, Norman L. Block, Gunhild Keller, Ferenc G. Rick, Karoly Szepeshazi, Gabor Halmos, Andrew V. Schally
Publikováno v:
Oncotarget
Scopus-Elsevier
Scopus-Elsevier
// Karoly Szepeshazi 1,2 , Andrew V. Schally 1,2,3,4,5 , Gunhild Keller 6 , Norman L. Block 1,2,3,4 , Daniel Benten 7 , Gabor Halmos 1,2,3,8 , Luca Szalontay 1,2 , Irving Vidaurre 1,2 , Miklos Jaszberenyi 1,2,3 , Ferenc G. Rick 1,2,3 1 Veterans Affai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c84beccd018a4a6fd24491f207fda3
https://doi.org/10.18632/oncotarget.546
https://doi.org/10.18632/oncotarget.546
Autor:
Tim H. Brümmendorf, Jörg Schrader, Ansgar W. Lohse, Melanie Braig, Stefan Balabanov, Artur Gontarewicz, Henning Wege, Alexander Quaas, Daniel Benten, Gunhild Keller, Jürgen Moll
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 11, Iss 9, Pp 934-944 (2009)
Patients with advanced stages of hepatocellular carcinoma (HCC) face a poor prognosis. Although encouraging clinical results have been obtained with multikinase inhibitor sorafenib, the development of improved therapeutic strategies for HCC remains a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e92a7203da9a7b7708a54787066c93f
https://doi.org/10.1593/neo.09664
https://doi.org/10.1593/neo.09664
Publikováno v:
Hematological Oncology. 27:123-129
Telomeres are specialized structures localized at the end of human chromosomes. Due to the end replication problem, each cell division results in a loss of telomeric repeats in normal somatic cells. In germ line and stem cells, the multicomponent enz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c45181f9004f77dfc1f3cf73fff185
https://doi.org/10.1002/hon.901
https://doi.org/10.1002/hon.901
Autor:
Jürgen Moll, Riccardo Colombo, Enrico Pesenti, Gunhild Keller, Stefan Balabanov, Daniel Benten, Tim H. Brümmendorf, Alessio Graziano, Artur Gontarewicz, Carsten Bokemeyer, Walter Fiedler
Publikováno v:
Blood. 111:4355-4364
The emergence of resistance to imatinib (IM) mediated by mutations in the BCR-ABL domain has become a major challenge in the treatment of chronic myeloid leukemia (CML). Here, we report on studies performed with a novel small molecule inhibitor, PHA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4886482d5677cc1c733890fa5b52ff9
https://doi.org/10.1182/blood-2007-09-113175
https://doi.org/10.1182/blood-2007-09-113175
Autor:
David Schrama, Wolfram Fink, Marc Zapatka, Jürgen C. Becker, Roland Houben, Gunhild Keller, Dirk Schadendorf, Selma Ugurel, Eva-Bettina Bröcker, Howard L. Kaufman
Publikováno v:
Cancer Immunology, Immunotherapy. 57:685-691
Chemokines influence both tumor progression and anti-tumor immune response. A 32-bp-deletion polymorphism in the chemokine receptor 5 gene (CCR5Delta32) has been shown to result in a non-functional protein. This study was aimed at evaluating the pote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a75d7372ca1020d9865d242b0d2fae31
https://doi.org/10.1007/s00262-007-0407-z
https://doi.org/10.1007/s00262-007-0407-z
Autor:
Donata Grimm, Linn Woelber, Gunhild Keller-von Amsberg, Volkmar Mueller, Fabian Trillsch, Isabell Witzel, Sven Mahner, Katharina Prieske
Publikováno v:
Frontiers in Oncology, Vol 5 (2015)
Frontiers in Oncology
Frontiers in Oncology
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::519bbc92ffc7dcefd84754872980a1d8